Last reviewed · How we verify
Enalapril/hydrochlorothiazide
Enalapril inhibits angiotensin-converting enzyme (ACE) to reduce angiotensin II production, while hydrochlorothiazide acts as a thiazide diuretic to promote sodium and water excretion, together lowering blood pressure.
Enalapril inhibits angiotensin-converting enzyme (ACE) to reduce angiotensin II production, while hydrochlorothiazide acts as a thiazide diuretic to promote sodium and water excretion, together lowering blood pressure. Used for Hypertension, Heart failure.
At a glance
| Generic name | Enalapril/hydrochlorothiazide |
|---|---|
| Also known as | To be determined |
| Sponsor | Erasmus Medical Center |
| Drug class | ACE inhibitor / thiazide diuretic combination |
| Target | Angiotensin-converting enzyme (ACE); sodium-chloride cotransporter |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Enalapril blocks ACE, preventing conversion of angiotensin I to angiotensin II, which reduces vasoconstriction and aldosterone secretion. Hydrochlorothiazide increases urinary sodium and water loss, reducing blood volume and peripheral vascular resistance. The combination provides synergistic antihypertensive effects through complementary mechanisms.
Approved indications
- Hypertension
- Heart failure
Common side effects
- Cough
- Dizziness
- Hyperkalemia
- Hypokalemia
- Hypotension
- Headache
- Fatigue
Key clinical trials
- Phototoxicity of Frequently Prescribed Medicines (NA)
- Peripheral Vascular Effects of Sulfhydryl-containing Antihypertensive Pharmacotherapy on Microvessels in Humans (PHASE1, PHASE2)
- Enalapril Folic Acid Tablets Combined With CCB or Diuretic to Prevent Stroke in Patients With Type H Hypertension (PHASE3)
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Coronavirus (COVID-19) ACEi/ARB Investigation (PHASE4)
- Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians Using a Single PolyPill (PHASE3)
- Systolic Hypertension in Europe Placebo-Controlled Trial (PHASE2)
- Feasibility Study of the Intensive Systolic Blood Pressure Control (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Enalapril/hydrochlorothiazide CI brief — competitive landscape report
- Enalapril/hydrochlorothiazide updates RSS · CI watch RSS
- Erasmus Medical Center portfolio CI